Premium
CLONAZEPAM IN THE TREATMENT OF EPILEPSY
Author(s) -
Huang C. Y.,
McLeod J. G.,
Sampson D.,
Hensley W. J.
Publication year - 1974
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1974.tb93563.x
Subject(s) - clonazepam , epilepsy , benzodiazepine , medicine , refractory (planetary science) , temporal lobe , petit mal , anesthesia , pharmacology , psychiatry , physics , receptor , astrobiology
Clonazepam, a benzodiazepine derivative, has been used in the treatment of 46 patients with epilepsy who have failed to respond to treatment with other anticonvulsants. Plasma levels of the drug have been measured. It is particularly effective in the treatment of myoclonic epilepsy and self‐induced photogenic seizures, but also has a role in the therapy of refractory petit mal and temporal lobe epilepsy. The usual effective oral dose of the drug is 6 mg/day, which maintains a plasma level of about 25 to 30 ng/ml.